Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of EBITDA Margin data on record, last reported at 3012.55% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 301286.0% year-over-year to 3012.55%; the TTM value through Dec 2025 reached 562.74%, down 59377.0%, while the annual FY2025 figure was 562.74%, 59377.0% down from the prior year.
  • EBITDA Margin reached 3012.55% in Q4 2025 per TRDA's latest filing, down from 2720.76% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 82.25% in Q3 2023 and bottomed at 3012.55% in Q4 2025.
  • Average EBITDA Margin over 3 years is 674.98%, with a median of 43.1% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: surged 20272bps in 2024, then tumbled -301286bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 21.16% in 2023, then skyrocketed by 101bps to 0.31% in 2024, then tumbled by -971335bps to 3012.55% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 3012.55% in Q4 2025, 2720.76% in Q3 2025, and 2212.31% in Q2 2025.